Skip to main content
. 2017 Jul 17;3:17037. doi: 10.1038/cddiscovery.2017.37

Figure 2.

Figure 2

Reduced toxicity of masked lytic peptides. (a) Lactate dehydrogenase release of MDA-MB-231 cells following treatment with Uk14, Ur11, e8-Uk14, e7-Ur11 (4 h treatment). (b) Haemolysis assays for Uk14, Ur11, e8-Uk14, e7-Ur11 in red blood cells. (1 h treatment). (c) Caspase activation in MDA-MB-231 cells following treatment with Uk14 (5 μM, 4 h treatment), Ur11 (10 μM, 4 h treatment) and ABT-737 (10 μM, 4 h treatment). Action of ABT-737 (d) or peptides Ur11 and Uk14 (e) with or without Z-VAD-FMK on MDA-MB-231 (24 h treatment). Small letters in the sequences indicate D-amino-acids. U=Aib, α-aminoisobutyric acid. Error bars represent the standard deviation from more than at least two independent experiments. *P<0.05, **P<0.01, ***P<0.001 compared with corresponding unmasked peptides-treated cells (Uk14 versus e8-Uk14, Ur11 versus e7-Ur11) in a and b, ABT-737-treated cells in d and cells without treatment of Z-VAD-FMK in d and e.